Last updated: 2026-09-22 01:44:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Eloxx Pharmaceuticals, Inc. (ELOX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $17.43, with a market capitalization of $59.96M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.92 to $23.40. This page covers its latest market performance, valuation, price trends and company information.
$59.96M | |
$17.36 | |
$10,824.00 | |
$16.92 | |
$17.45 | |
17.48K | |
52.12K | |
-- | |
$23.40 | |
$16.92 | |
-- | |
-- |
Eloxx Pharmaceuticals, Inc. (ELOX) last closed at $17.45 as of 2026-09-21 23:31:00, unchanged from the previous close of $17.45.
During the latest regular trading session, ELOX traded between $16.92 and $10,824.00, with a volume of 17.48K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Eloxx Pharmaceuticals, Inc. (ELOX) moved from $16.28 to $17.43, representing a gain of 7.08% ($1.15).
The stock traded between $15.00 and $18.98 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 28.58 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 8.0%
ELOX is currently trading at $17.43, placing it 8.0% of the way from its 52-week low of $16.92 to its 52-week high of $23.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Eloxx Pharmaceuticals, Inc. (ELOX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.